Overview and research progress of tumorigenesis and related therapies of Uterine leiomyomas

Abstract

Abstract: Uterine leiomyomas, also called fibroids, are the most common reproductive tract neoplasm in premenopausal women.The discovery and development of medicinal therapies for uterine leiomyoma have been hampered by a lack of understanding in terms of the etiology and molecular mechanisms underlying the development of these lesions.As a reference, this article reviews mechanisms of the tumorigenesis and medicinal therapies, including genes, hormones, growth factors and some other pathways, in order to understand the tumor well and find more promising new drugs.

Key words: uterine leiomyoma, mechanisms, therapy

CLC Number:

R711.74

LIU Lin-yan, YUAN Sheng-tao, YU Bo-yang. Overview and research progress of tumorigenesis and related therapies of Uterine leiomyomas[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 140-146.

References

[1] Walker CL, Stewart EA.Uterine Fibroids:The Elephant in the Room[J]. Science, 2005;10:1589-1592.
[2] Baysal BE.Krebs cycle enzymes as tumor suppressors[J]. Drug Discov Today, 2005;2:247-254.
[3] Cook JD, Walker CL.Treatment strategies for uterine leiomyoma: the role of hormonal modulation[J]. Semin Reprod Med,2004;22:105-111.
[4] Barbarisi A, Petillo O, Di Lieto A, et al. 17β-estradiol elicits an autocrine leiomyoma cell proliferation:evidence for a stimulation of protein kinase-dependent pathway[J]. J Cell Physiol,2001;186:414-424.
[5] Maruo T, Ohara N, Wang J, et al. Sex steroidal regulation of uterine leiomyoma growth and apoptosis[J]. Hum Reprod Update, 2004;10:207-220.
[6] Swartz CD, Afshari CA, Yu L, et al. Estrogen-induced changes in IGF-I, Myb family andMAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines[J]. Mol Hum Reprod, 2005;11:441-450.
[7] Kasai T, ShozuM, Murakami K, et al. Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma[J]. J Clin EndocrinolMetab, 2004;89:5661-5668.
[8] Al-Hendy A, Salama SA.Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups[J]. J Soc Gynecol Investig, 2006;13:136-144.
[9] Schultze-Mosgau A, Griesinger G, Altgassen C, et al. New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists[J]. Expert Opin Investig Drugs,2005;14:1085-1097.
[10] Hummel CW, Geiser AG, Bryant HU, et al. A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats[J]. J Med Chem, 2005;48:6772-6775.
[11] DeManno D, Elger W, Garg R, et al. Asoprisnil (J867):a selective progesterone receptor modulator for gynecological therapy[J]. Steroids, 2003;68:1019-1032.
[12] ChenW, Ohara N, Wang J, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells[J]. J Clin Endocrinol Metab, 2006;91:1296-1304.
[13] Wang J, Ohara N, Wang Z, et al. A novel selective progester- one receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGF {beta}3 and their receptors in cultured uterine leiomyoma cells[J]. Hum Reprod, 2006;21:1869-1877.
[14] Al-Hendy A.Gene Therapy of uterine fibroids:adenovirus-mediated expression of dominant negative estrogen receptor inhibits ERE-reporter transactivation in rat and human leiomyoma cells[J]. Mol Ther, 2005;11:S213.
[15] Sumitani H, Shozu M, Segawa T, et al. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine intracrine mechanism[J]. Endocrinology, 2000;141:3852-3861.
[16] Shozu M, Murakami K, Segawa T, et al. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausalwoman with a nonsteroidal aromatase inhibitor[J]. Fertil Steril, 2003; 79:628-629.
[17] Luo X, Ding L, Xu J, et al. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta[J]. Endocrinology, 2005;146:1097-1118.
[18] WolanskaM, Bankowski E.Fibroblast growth factors (FGF) in human myometrium and uterine leiomyomas in various stages of tumour growth[J]. Biochimie, 2006;88:141-146.
[19] Nowak RA.Novel therapeutic strategies for leiomyomas:targeting growth factors and their receptors[J]. Environ Health Perspect, 2000;108(Suppl 5):849-853.
[20] Shushan A, Rojansky N, Laufer N, et al. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth[J]. Hum Reprod, 2004;19:1957-1967.
[21] Niu H, Simari RD, Zimmermann EM, et al. Nonviral vectormediated thymidine kinase gene transfer and ganciclovir treatment in leiomyoma cells[J]. Obstet Gynecol, 1998;91:735-740.
[22] Al-Hendy A, Kamel M, Christman G, et al. Uterine fibroids gene therapy:adenovirus-mediated herpes simplex virus thymidine kinase ganciclovir treatment inhibits growth of human and rat leiomyoma cells[J]. Mol Ther, 2005;11:S102.
[23] Gamage SD, Bischoff ED, Burroughs KD, et al. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma[J]. J Pharmacol Exp Ther, 2000;295:677-681.
[24] Adolfsson PI, Haug I, Berg G, et al. Changes in beta(2)-adrenoceptor expression and in adenylyl cyclase and phosphodiesterase activity in human uterine leiomyomas[J]. Mol Hum Reprod, 2000;6:835-842.
[25] Houston KD, Copland JA, Broaddus RR, et al. Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor-ligands in uterine leiomyoma1[J]. Cancer Res, 2003;63:1221-1227.
[26] Kim BY, Cho CH, Song DK, et al. Ciglitizone inhibits cell proliferation in human uterine leiomyoma via activation of storeoperated Ca²+ channels[J]. Am J Phy siol Cell Physiol, 2005; 88:C389-C395.
[27] Loy CJ, Evelyn S, Lim FK, et al. Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-gamma ligand, pioglitazone[J]. Mol Hum Reprod, 2005;1:561-566.
[28] Nowak RA.Drug therapies for uterine fibroids:a new approach to an old problem[J]. Drug Discovery Today:Therapeutic Strategies, 2004;1:237-242.